1. Introduction {#sec1}
===============

The consensus group at the Second International Workshop on Waldenström\'s macroglobulinemia (WM) in 2002 redefined WM as a distinct clinicopathologic entity characterized by bone marrow infiltration by lymphoplasmacytic lymphoma (LPL) and immunoglobulin M (IgM) monoclonal gammopathy \[[@B1]\]. Diagnostic criteria for WM are IgM monoclonal gammopathy of any concentration, bone marrow infiltration by small lymphocytes showing plasmacytoid or plasma cell differentiation, intertrabecular pattern of bone marrow infiltration, and surface IgM^+^, CD5^±^, CD10^−^, CD19^+^, CD20^+^, CD22^+^, CD23^−^, CD25^+^, CD27^+^, FMC7^+^, CD103^−^, and CD138^−^ immunophenotype \[[@B2]\].

WM is a very rare lymphoid malignancy, with an overall incidence estimated at 0.35 for WM and 0.63 for LPL/WM per 100,000 person-years during 2001--2003, representing 1.2% or 2.1% of all non-Hodgkin\'s lymphomas in the United States Surveillance Epidemiology and End Results (SEER) cancer registries, respectively \[[@B3]\]. Between 1996 and 2003, the crude incidence of LPL/WM was 0.078 per 100,000 person-years in Japan (0.112 for men and 0.048 for women) and 0.032 per 100,000 person-years in Taiwan (0.042 for men and 0.021 for women) \[[@B4]\]. A previous nationwide survey of the incidence of lymphoma based on the REAL classification reported the incidence of LPL in Korea as 0.8%, with the exact incidence rate of WM/LPL not recognized \[[@B5]\]. The incidence rate of WM is lower in the Republic of Korea than those in the USA, which was documented to be about 0.3 per million person-years according to data of the National Cancer Information Center in the Republic of Korea.

The most common clinical manifestations are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%) \[[@B6]\]. The most common presenting symptom is fatigue related to normochromic or normocytic anemia. The median hemoglobin value at diagnosis is 10 g/dL \[[@B7]\]. Patients with a disease-related hemoglobin level \<10 g/dL, platelet count \<100 × 10^9^/L, bulky adenopathy or organomegaly, symptomatic hyperviscosity, moderate to severe or advancing peripheral neuropathy on the basis of disease, symptomatic amyloidosis, cryoglobulinemia, or cold-agglutinin disease should be considered for therapy but asymptomatic patients should be observed \[[@B8]\]. Recently, the superior efficacy of chemotherapy combined with novel agent including rituximab, bendamustine, bortezomib, lenalidomide, and thalidomide than that of conventional chemotherapy has been established. However, little is known about the clinical features, epidemiology, and cytogenetics of WM in Asia including the Republic of Korea. Novel agent combined chemotherapy for patients with WM has been restricted in the Republic of Korea because of very low incidence and insurance coverage limitation.

Treatment outcomes in the Republic of Korea patients with WM treated by novel agent combined chemotherapy are unclear. This study is aimed at investigating the clinical features and assess the treatment outcomes of novel agent combined chemotherapy and conventional chemotherapy.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

Data from 71 patients newly diagnosed with WM who received chemotherapy at 17 university hospitals in the Republic of Korea between January 2005 and December 2012 were collected retrospectively. All cases fulfilled the diagnostic criteria \[[@B1]\] and were confirmed as WM by hematopathologists and hematologists. The pretreatment evaluation included a physical examination with performance status evaluation, complete blood cell count with differential count, blood chemistry including lactase dehydrogenase (LDH), protein electrophoresis (PEP), IgM, free light chain kappa and lambda, bone marrow biopsy, chromosomal study, fluorescence in situ hybridization (FISH), and computed tomography (CT) of the chest, abdomen, and pelvis.

2.2. Treatment {#sec2.2}
--------------

All patients were treated with conventional chemotherapy or chemotherapy along with novel agent (rituximab, bortezomib, thalidomide, and bendamustine). Bendamustine is old chemotherapeutic agent but recently the roles of this drug were rediscovered by its efficacy and toxicities in indolent lymphoma including WM \[[@B9], [@B10]\]. Rituximab combined chemotherapy included rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Bortezomib combined chemotherapy included bortezomib plus dexamethasone (VD). Thalidomide combined chemotherapy included thalidomide plus dexamethasone (TD) and thalidomide plus cyclophosphamide and dexamethasone (TCD). Bendamustine was used along with prednisolone. Conventional chemotherapy included chlorambucil, CVP, CHOP, melphalan plus prednisolone (MP), cyclophosphamide plus prednisolone (CP), fludarabine plus cyclophosphamide (FC), and fludarabine plus cyclophosphamide and mitoxantrone (FCM). All patients were treated with one or more chemotherapeutic regimens. Patients who displayed progression or intolerance against previous chemotherapy were changed from chemotherapy to a salvage regimen. Introduction of novel agents was applied to four patients as first-line, three as second-line, five at third-line, and two at fourth-line chemotherapy.

2.3. Analysis {#sec2.3}
-------------

Overall response rates (ORR) of patients treated with conventional and novel therapy were estimated as the best response at first-line and applied periods. ORR were estimated by clinical parameters in all patients including age, sex, hemoglobin levels, platelet counts, absolute lymphocyte counts (ALC), C-reactive protein (CRP), LDH, serum *β*2-microglobulin, serum albumin, hepatosplenomegaly, Eastern Cooperative Oncology Group (ECOG) performance status, presence of B symptoms, and hyperviscosity syndrome. Those clinical parameters and international staging system (ISS), International Prognostic Scoring System for Waldenstrom\'s Macroglobulinemia (ISSWM), and treatment modalities were estimated to find prognostic markers for survival. The treatment response was assessed according to the Sixth International Workshop on WM \[[@B11]\].

2.4. Statistical Analyses {#sec2.4}
-------------------------

We investigated independent prognostic factors associated with survival in above clinical and laboratory parameters. The definition of overall survival (OS) was calculated from the date of diagnosis to the date of death from disease-related cause or final follow-up date. Progression-free survival (PFS) was from the date of starting treatment (conventional chemotherapy or novel agent combined chemotherapy) to the date of disease progression, relapse, or death from disease-related cause. Associations between the clinical parameters and ORR were analyzed using the chi-square test. A multiple logistic regression analysis was used for multivariate analysis of independent prognostic factors for ORR. Survival probabilities were calculated according to the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards regression model was used for multivariate analysis of independent prognostic factors for survival. Information about the baseline medical status and treatment modalities was collected from the medical records. Approval for these studies was obtained from the Institutional Review Board.

3. Results {#sec3}
==========

3.1. Clinical and Laboratory Characteristics {#sec3.1}
--------------------------------------------

The median age of the 71 patients was 66 years (range: 37--92 years) and the male to female ratio was 5 : 1 ([Table 1](#tab1){ref-type="table"}). 25.4% and 38.0% of patients had clinical or radiological evidence of splenomegaly and of lymphadenopathy, respectively. 11.3% of patients had B symptoms before the initiation of treatment. Hyperviscosity and involvement of other organs were shown in 11.3% and 40.8% of patients, respectively. The median serum monoclonal protein level was 3.640 g/dL (range: 0.0183--10.795). The cytogenetic abnormalities identified included deletion of the long arm of chromosome 6 in two cases and absence of trisomy 4. Other cytogenetic abnormalities were identified in 11.3% of cases. Other clinical or laboratory characteristics are summarized in [Table 1](#tab1){ref-type="table"}.

3.2. Treatment and Outcomes {#sec3.2}
---------------------------

The 71 patients were treated with novel agent combined chemotherapy or conventional chemotherapy. 25 patients were treated with chlorambucil with or without prednisone, 14 were treated with CVP or CHOP regimen, 15 were treated with the MP or CP regimen, and three were treated with FC or FCM as first-line therapy. Other patients were treated with novel agent combined chemotherapy. Six patients were treated with R-CVP, R-CHOP, five with VD, two with thalidomide plus dexamethasone, and one with bendamustine plus prednisolone ([Table 1](#tab1){ref-type="table"}). Overall, an objective response (complete or partial response) and more than minimal response (MR) rates were documented in 53.5% and 69.0% of patients, respectively. The median follow-up was 22.97 months. The 5-year PFS and OS rates were 50.5% and 62.6% (95% confidence interval (95% CI): 48.32--81.41 and 34.73--111.07), respectively.

3.3. Analysis of Prognostic Factors for Response and Survival {#sec3.3}
-------------------------------------------------------------

Multiple parameters were analyzed for their possible prognostic impact on ORR and OS. Univariate analysis showed that the following factors were associated with higher ORR ([Table 2](#tab2){ref-type="table"}): higher ALC (\<1.0 × 10^9^/L versus ≥1.0 × 10^9^/L; 20.0% versus 64.6%, *P* = 0.069), good ECOG performance status (\<2 versus ≥2; 67.4 versus 43.5, *P* = 0.057), and novel agent combined chemotherapy versus conventional chemotherapy (92.9% versus 52.6%, *P* = 0.006). The following factors were associated with superior 5-year OS ([Table 2](#tab2){ref-type="table"}): younger age (\<65 years versus ≥65 years; 82.2% versus 36.8%, *P* = 0.024), good ECOG performance status (\<2 versus ≥2; 72.6% versus 26.9%, *P* = 0.004), higher serum albumin levels (\<3.5 g/dL versus ≥3.5 g/dL; 44.8% versus 84.1%, *P* = 0.010), lower risk international staging system (ISS I, II, and III; 85.7%, 84.8%, and 36.8%, resp.; *P* = 0.004), and novel agent combined chemotherapy versus conventional chemotherapy (100% versus 53.0%, *P* = 0.067). In the multivariate analysis, novel agent combined chemotherapy was an independent prognostic value for ORR (*P* = 0.046) and lower ISS was an independent prognostic value for OS (*P* = 0.008) ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

The clinical manifestations and laboratory abnormalities associated with WM are related to direct tumor infiltration and to the amount and specific properties of monoclonal IgM. The most common symptoms are weakness and fatigue, usually secondary to anemia. Symptoms of weight loss, excessive sweating, and low-grade fever affect a quarter of patients. Hepatomegaly, splenomegaly, and lymphadenopathy each occur in 15%--30% of patients. Similarly, previous Korean studies reported the most common symptoms as anemia and thrombocytopenia, with other frequently expressed symptoms being (20--40%), hepatosplenomegaly (25--35%), and lymphadenopathy (25--40%) \[[@B12]--[@B14]\]. In this study, anemia was the most frequent symptom and thrombocytopenia was secondary frequent symptom with lymphadenopathy, hepatomegaly, and splenomegaly being expressed in 10--40% of the cases. However, hyperviscosity syndrome was documented only in eight cases, which was a relatively low incidence compared to western results \[[@B6]\]. The most common cytogenetic abnormality was deletion of the long arm of chromosome 6 (6q deletion) and trisomy 4 \[[@B15], [@B16]\]. However, there was only one report about cytogenetics of Korean WM patients, which documented a low rate of 6q deletion (10%) and no trisomy 4 \[[@B13]\]. Similar to a previous Korean study, this study documented a low rate of 6q deletion and other cytogenetic abnormalities.

In this study, novel agent combined chemotherapy was the only independent predictive factor for response rates, although higher ALC count and good performance status were also associated with higher ORR in univariate analysis. Many studies have been shown to improve response and survival rates in patients with WM. Gertz et al. presented meaningful results about efficacy of rituximab in patients with WM \[[@B17]\]. The efficacy of rituximab in WM has been amply described. Rituximab combined chemotherapy including R-CHOP, R-CVP, R-CP, R-F (fludarabine), R-cladribine, and R-CD (cyclophosphamide and dexamethasone) produces superior response rates to conventional chemotherapy \[[@B18]--[@B23]\]. Rituximab combined with thalidomide reportedly produced a 72% response rate, and rituximab combined with lenalidomide produced a 50% response rate \[[@B24], [@B25]\]. Bortezomib has high levels of activity in the management of relapsed WM with response rates ranging from 81% to 96% \[[@B26], [@B27]\]. In a prospective randomized study of bendamustine plus rituximab compared with R-CHOP in patients with WM, of whom 22 received bendamustine and rituximab and 19 received R-CHOP, the response rate was 95% in both groups, but median progression-free survival was significantly prolonged with bendamustine. The median progression-free survival for R-CHOP was 36 months in contrast to not being reached with bendamustine and rituximab (*P* \<  0.0001) \[[@B28]\].

In our study, only lower risk ISS showed superior survival to those of higher risk ISS although younger age, good performance status, higher serum albumin levels, and novel agent combined chemotherapy were associated with longer OS in univariate analysis. Patients treated with novel agent combined chemotherapy especially did not show superior survival rates to conventional chemotherapy in spite of higher ORR in patients receiving novel agents. These results might be associated with small sample size, short follow-up duration, and the clinical features of WM (which seems to be indolent lymphoma). Prior studies have documented several prognostic factors for survival \[[@B29]--[@B33]\]. Age, anemia, leukopenia, thrombocytopenia, serum albumin levels, and *β*2-microglobulin values were linked to survival. However, these prognostic factors were not meaningful in this study. Very low incidence rates of WM and restriction of using novel agents because of the limitation of medical reimbursement in Korea might be reasons for the insufficient comparison between novel agent combined chemotherapy and conventional chemotherapy in this study.

5. Conclusions {#sec5}
==============

Clinical features of Korean WM are similar to western WM, except for the low incidence of hyperviscosity syndrome. Response rates after chemotherapy were improved by introduction of novel agents such as rituximab, bortezomib, thalidomide, and bendamustine, although survival benefit was not shown. Independent prognostic factor for survival was high risk ISS in Korean WM. However, further study with more patients is needed to determine the efficacy of novel agent combined chemotherapy and to definitively identify the prognostic factors.
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###### 

Clinical and laboratory characteristics.

  Characteristic                                    *N* (%) or median (range)
  ------------------------------------------------- ---------------------------
  Patients                                          71
  Age, years, median (range)                        66 (37--92)
  Gender                                             
   Male                                             59 (83.1)
   Female                                           12 (16.9)
  Hemoglobin, g/dL, median (range)                  9.6 (3.80--17.10)
  Platelet count, ×10^9^/L, median (range)          213 (23--575)
  ALC, ×10^9^/L, median (range)                     1.70 (0.10--12.30)
  CRP, mg/dL, median (range)                        2.44 (0.05--23.80)
  Serum *β*2-microglobulin, mg/L, median (range)    4.20 (1.34--30.00)
  Serum albumin, g/dL, median (range)               3.2 (1.50--4.60)
  LDH, IU/L, median (range)                         261.0 (74.0--968.0)
  BM lymphocyte, %, median (range)                  14 (5--100)
  Cytogenetic abnormalities, present (%)            8 (11.3%)
  Serum monoclonal protein, mg/dL, median (range)   3640.0 (18.30--10795.0)
  B symptom, present (%)                            8 (11.3)
  ECOG (%) ≥2                                       23 (32.4)
  Hyperviscosity, present (%)                       8 (11.3)
  Lymphadenopathy, yes (%)                          27 (38.0)
  Extranodal involvement, yes (%)                   29 (40.8)
  Splenomegaly, yes (%)                             18 (25.4)
  Hepatomegaly, yes (%)                             7 (9.9)
  ISS (%)                                            
   I                                                13 (18.3)
   II                                               26 (36.6)
   III                                              26 (36.6)
   Unknown                                          6 (8.5)
  Treatment regimen                                  
   Novel agent combined  chemotherapy               14 (19.7)
   Conventional chemotherapy                        57 (80.3)
  Treatment                                          
  Novel group                                        
   R-combined CTx; R-CVP, R-CHOP                    6 (8.5)
   VD                                               5 (7.0)
   TD                                               2 (2.8)
   Bendamustine plus prednisolone                   1 (1.4)
  Conventional group                                 
   Chlorambucil                                     25 (35.2)
   CVP or CHOP                                      14 (19.7)
   MP or CP                                         15 (21.1)
   FC or FCM                                        3 (4.2)

ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; BM: bone marrow; ECOG: Eastern Cooperative Oncology Group performance status; ISS: international staging system; R-combined CTx: rituximab combined chemotherapy; R-CVP: rituximab, cyclophosphamide, vincristine, and prednisolone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; VD: bortezomib plus dexamethasone; TD: thalidomide plus dexamethasone; MP: melphalan plus prednisolone; CP: cyclophosphamide plus prednisolone; FC: fludarabine plus cyclophosphamide; FCM: fludarabine plus cyclophosphamide and mitoxantrone.

###### 

Clinical and laboratory values associated with survival on univariate analysis.

  Characteristic                       ORR ≥ PR (%)   *P*     5-year PFS (%)   *P*     5-year OS (%)   *P*
  ------------------------------------ -------------- ------- ---------------- ------- --------------- -------
  Age, years                                                                                            
   \<65                                66.7           0.327   64.8             0.708   82.2            0.024
   ≥65                                 55.3           37.0    36.8                                     
  Gender                                                                                                
   Male                                64.4           0.197   46.8             0.530   65.9            0.130
   Female                              41.7           77.9    45.0                                     
  BM lymphocyte, %                                                                                      
   \<50                                63.0           0.461   61.8             0.478   40.6            0.610
   ≥50                                 52.9           26.2    52.5                                     
  Cytogenetic abnormalities                                                                             
   Presence                            75.0           0.466   64.3             0.599   50.0            0.444
   Absence                             58.7           50.9    42.4                                     
  Hemoglobin, g/dL                                                                                      
   \<11.5                              61.3           0.732   54.3             0.140   60.2            0.700
   ≥11.5                               55.6           0.0     87.5                                     
  Platelet count, ×10^9^/L                                                                              
   \<100                               69.2           0.479   0.0              0.049   61.9            0.124
   ≥100                                58.6           60.6    63.0                                     
  ALC, ×10^9^/L                                                                                         
   \<1.0                               20.0           0.069   33.3             0.611   40.0            0.224
   ≥1.0                                64.6           54.3    64.6                                     
  CRP, mg/dL                                                                                            
   \<5                                 58.0           0.817   46.4             0.937   65.5            0.096
   ≥5                                  61.5           51.3    48.6                                     
  Serum *β*2-microglobulin, mg/L                                                                        
   \<3                                 66.7           0.862   48.9             0.130   50.0            0.143
   ≥3                                  64.0           50.6    58.4                                     
  Serum albumin, g/dL                                                                                   
   \<3.5                               58.5           0.683   43.1             0.712   44.8            0.010
   ≥3.5                                63.3           64.4    84.1                                     
  LDH, IU/L                                                                                             
   \<450                               59.7           0.688   50.1             0.849   61.8            0.403
   ≥450                                66.7           65.6    72.9                                     
  B symptom                                                                                             
   Presence                            87.5           0.132   83.3             0.666   60.0            0.385
   Absence                             56.5           48.8    62.8                                     
  ECOG, (%)                                                                                             
   0-1                                 67.4           0.057   68.7             0.012   72.6            0.004
   ≥2                                  43.5           18.1    26.9                                     
  Hyperviscosity syndrome                                                                               
   Presence                            25.0           0.055   58.3             0.980   0.0             0.918
   Absence                             63.8           49.7    66.2                                     
  Splenomegaly                                                                                          
   Presence                            61.1           0.838   77.4             0.342   0.0             0.300
   Absence                             58.3           49.5    52.7                                     
  Hepatomegaly                                                                                          
   Presence                            57.1           0.884   40.0             0.246   28.6            0.913
   Absence                             60.0           42.5    45.1                                     
  ISSWM (%)                                                                                             
   Low                                 57.1           0.567   66.7             0.912   50.0            0.380
   Intermediate                        58.8           58.7    58.0                                     
   High                                75.0           0.0     58.4                                     
  ISS (%)                                                                                               
   I                                   61.5           0.522   48.7             0.714   85.7            0.004
   II                                  69.2           41.9    84.8                                     
   III                                 53.8           64.7    36.8                                     
  Treatment regimen                                                                                     
   Novel agent combined chemotherapy   92.9           0.006   79.1             0.418   100.0           0.067
   Conventional chemotherapy           52.6           46.3    53.0                                     

ORR: overall response rates; PR: partial response rates; 5-year PFS: 5-year progression-free survival rates; 5-year OS: 5-year overall survival rates; BM: bone marrow; ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; ECOG: Eastern Cooperative Oncology Group performance status; ISSWM: International Prognostic Scoring System for Waldenstrom\'s Macroglobulinemia; ISS: international staging system.

###### 

Multivariate analysis for response and survival.

  Value                                ORR     OS                                             
  ------------------------------------ ------- --------------- ------- ------- -------------- -------
  Age, years                                                                                   
   \<65                                                                                        
   ≥65                                                                 1.021   0.350--2.980   0.970
  ALC, ×10^9^/L                                                                                
   \<1.0                                                                                       
   ≥1.0                                0.362   0.060--2.193    0.369                           
  ECOG (%)                                                                                     
   0-1                                                                                         
   ≥2                                  2.006   0.711--5.660    0.188   0.421   0.147--1.208   0.108
  Serum albumin, g/dL                                                                          
   \<3.5                                                                                       
   ≥3.5                                                                1.123   0.264--4.772   0.875
  ISS (%)                                                                                      
   I                                                                                           
   II                                                                  0.439   0.078--2.486   0.352
   III                                                                 0.209   0.066--0.665   0.008
  Treatment regimen                                                                            
   Novel agent combined chemotherapy                                                           
   Conventional chemotherapy           5.048   1.032--24.702   0.046   0.368   0.075--1.803   0.217

ORR: overall response rates; OS: overall survival rates; RR: relative risk; 95% CI: 95% confidence interval; ALC: absolute lymphocyte count; ECOG: Eastern Cooperative Oncology Group performance status; ISS: international staging system.
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